UnitedHealthcare Pharmacy
Clinical Pharmacy Programs
Program Number 2025 P 2320-3
Program Prior Authorization/Medical Necessity
Medication * Omvoh™ (mirikizumab-mrkz)
*This program applies to the subcutaneous formulation of Omvoh.
P&T Approval Date 1/2024, 1/2025, 3/2025
Effective Date 5/1/2025
1. Background:
Omvoh (mirikizumab-mrkz) is an interleukin-23 antagonist indicated for the treatment of
moderately to severely active ulcerative colitis in adults and moderately to severely active Crohn's
disease in adults.
2. Coverage Criteriaa:
A. Ulcerative Colitis (UC)
1. Initial Authorization for Maintenance Dosing
a. Omvoh will be approved based on all of the following criteria:
(1) Diagnosis of moderately to severely active ulcerative colitis
-AND-
(2) One of the following:
(a) Patient has been established on therapy with Omvoh under an active
UnitedHealthcare medical benefit prior authorization for moderately to severely
active ulcerative colitis
-OR-
(b) Both of the following:
i. Patient is currently on Omvoh therapy for moderately to severely active
ulcerative colitis as documented by claims history or submission of medical
records (Document date and duration of therapy):
-AND-
ii. Patient has not received a manufacturer supplied sample at no cost in the
prescriber’s office, or any form of assistance from an Eli Lilly sponsored
program (e.g., sample card which can be redeemed at a pharmacy for a free
supply of medication) as a means to establish as a current user of Omvoh*
-AND-
© 2025 UnitedHealthcare Services, Inc.
1
(3) Patient is not receiving Omvoh in combination with another targeted
immunomodulator [e.g., adalimumab, Cimzia (certolizumab), Enbrel
(etanercept), Entyvio (vedolizumab), Olumiant (baricitinib), Orencia (abatacept),
Rinvoq (upadacitinib), Simponi (golimumab), Skyrizi (risankizumab),
ustekinumab, Tremfya (guselkumab), Xeljanz/Xeljanz XR (tofacitinib), Zeposia
(ozanimod)]
-AND-
(4) Prescribed by or in consultation with a gastroenterologist
* Patients requesting initial authorization who were established on therapy via the receipt of a
manufacturer supplied sample at no cost in the prescriber’s office or any form of assistance from
an Eli Lilly sponsored program shall be required to meet initial authorization criteria as if
patient were new to therapy.
Authorization will be issued for 12 months.
2. Reauthorization
a. Omvoh will be approved based on both of the following criteria:
(1) Documentation of positive clinical response to Omvoh therapy
-AND-
(2) Patient is not receiving Omvoh in combination with another targeted
immunomodulator [e.g., adalimumab, Cimzia (certolizumab), Enbrel
(etanercept), Entyvio (vedolizumab), Olumiant (baricitinib), Orencia (abatacept),
Rinvoq (upadacitinib), Simponi (golimumab), Skyrizi (risankizumab),
ustekinumab, Tremfya (guselkumab), Xeljanz/Xeljanz XR (tofacitinib), Zeposia
(ozanimod)]
Authorization will be issued for 12 months.
B. Crohn’s Disease (CD)
1. Initial Authorization for Maintenance Dosing
a. Omvoh will be approved based on all of the following criteria:
(1) Diagnosis of moderately to severely active Crohn’s disease
-AND-
(2) One of the following:
© 2025 UnitedHealthcare Services, Inc.
2
(a) Patient has been established on therapy with Omvoh under an active
UnitedHealthcare medical benefit prior authorization for moderately to severely
active Crohn’s disease
-OR-
(b) Both of the following:
i. Patient is currently on Omvoh therapy for moderately to severely active
Crohn’s disease as documented by claims history or submission of medical
records (Document date and duration of therapy):
-AND-
ii. Patient has not received a manufacturer supplied sample at no cost in the
prescriber’s office, or any form of assistance from an Eli Lilly sponsored
program (e.g., sample card which can be redeemed at a pharmacy for a free
supply of medication) as a means to establish as a current user of Omvoh*
-AND-
(3) Patient is not receiving Omvoh in combination with another targeted
immunomodulator [e.g., adalimumab, Cimzia (certolizumab), Enbrel
(etanercept), Olumiant (baricitinib), Orencia (abatacept), Rinvoq (upadacitinib),
Simponi (golimumab), Skyrizi (risankizumab-rzaa), ustekinumab, Xeljanz
(tofacitinib)]
-AND-
(4) Prescribed by or in consultation with a gastroenterologist
Authorization will be issued for 12 months.
2. Reauthorization
a. Omvoh will be approved based on both of the following criteria:
(1) Documentation of positive clinical response to Omvoh therapy
-AND-
(2) Patient is not receiving Omvoh in combination with another targeted
immunomodulator [e.g., adalimumab, Cimzia (certolizumab), Enbrel
(etanercept), Olumiant (baricitinib), Orencia (abatacept), Rinvoq (upadacitinib),
Simponi (golimumab), Skyrizi (risankizumab-rzaa), ustekinumab, Xeljanz
(tofacitinib)]
Authorization will be issued for 12 months.
© 2025 UnitedHealthcare Services, Inc.
3
a State mandates may apply. Any federal regulatory requirements and the member specific
benefit plan coverage may also impact coverage criteria. Other policies and utilization
management programs may apply.
3. Additional Clinical Rules:
• Notwithstanding Coverage Criteria, UnitedHealthcare may approve initial and re-authorization
based solely on previous claim/medication history, diagnosis codes (ICD-10) and/or claim logic.
Use of automated approval and re-approval processes varies by program and/or therapeutic class.
• Supply limits may be in place.
• The intravenous infusion of is typically covered under the medical benefit. Please refer to the
UnitedHealthcare Drug Policy for Omvoh.
4. Reference:
1. Omvoh [package insert]. Indianapolis, IN: Eli Lilly and Company; January 2025.
Program Prior Authorization/Medical Necessity - Omvoh (mirikizumab-mrkz)
Change Control
1/2024 New program
1/2025 Annual review. Reworded criteria for established therapy through a
medical prior authorization for clarity and not to change clinical intent.
Updated examples with no change to clinical intent. Updated reference.
3/2025 Added coverage criteria for Crohn’s disease. Updated background and
references.
© 2025 UnitedHealthcare Services, Inc.
4